MX2021004994A - Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh). - Google Patents
Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).Info
- Publication number
- MX2021004994A MX2021004994A MX2021004994A MX2021004994A MX2021004994A MX 2021004994 A MX2021004994 A MX 2021004994A MX 2021004994 A MX2021004994 A MX 2021004994A MX 2021004994 A MX2021004994 A MX 2021004994A MX 2021004994 A MX2021004994 A MX 2021004994A
- Authority
- MX
- Mexico
- Prior art keywords
- pnh
- administration
- treatment
- paroxysmal nocturnal
- nocturnal hemoglobinuria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan métodos para el tratamiento clínico de la hemoglobinuria paroxística nocturna (PNH) que comprenden administrar al paciente un anticuerpo anti-C5, o un fragmento de unión al antígeno de este, donde el anticuerpo anti-C5, o fragmento de unión al antígeno de este, se administra (o es para administración) subcutáneamente de acuerdo con un régimen de dosificación clínico particular (es decir, en una cantidad de dosis particular y de acuerdo con un programa de dosificación específico). En una realización, el paciente ha sido tratado previamente con eculizumab (Soliris(r)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752563P | 2018-10-30 | 2018-10-30 | |
PCT/US2019/058846 WO2020092549A1 (en) | 2018-10-30 | 2019-10-30 | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004994A true MX2021004994A (es) | 2021-06-15 |
Family
ID=68621358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004994A MX2021004994A (es) | 2018-10-30 | 2019-10-30 | Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh). |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210395352A1 (es) |
EP (2) | EP3873602B1 (es) |
JP (2) | JP2022512632A (es) |
KR (1) | KR20210084533A (es) |
CN (1) | CN112996561A (es) |
AU (1) | AU2019370295A1 (es) |
BR (1) | BR112021008063A2 (es) |
CA (1) | CA3118282A1 (es) |
CO (1) | CO2021006290A2 (es) |
EA (1) | EA202191189A1 (es) |
ES (1) | ES2974217T3 (es) |
IL (1) | IL281990A (es) |
MX (1) | MX2021004994A (es) |
WO (1) | WO2020092549A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3658184T3 (da) | 2017-07-27 | 2023-11-27 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
US20230303670A1 (en) * | 2020-06-24 | 2023-09-28 | Alexion Pharmaceuticals, Inc. | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
US20240092881A1 (en) * | 2021-01-22 | 2024-03-21 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
UA105009C2 (uk) | 2008-08-05 | 2014-04-10 | Новартіс Аг | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
JP5878270B2 (ja) | 2012-12-19 | 2016-03-08 | プロメラス, エルエルシー | 高純度ノルボルネンアルカノールおよびその誘導体の製造方法 |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
TW201809008A (zh) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
WO2016160756A2 (en) * | 2015-03-31 | 2016-10-06 | Alexion Pharmaceuticlas, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
US20170182242A1 (en) * | 2015-12-27 | 2017-06-29 | Abbvie Inc. | Wearable Automatic Injection Device and Related Methods of Use |
US20190023775A1 (en) * | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
DK3468990T3 (da) | 2016-06-14 | 2024-06-24 | Regeneron Pharmaceuticals Inc | Anti-C5-antistoffer og anvendelser deraf |
DK3658184T3 (da) * | 2017-07-27 | 2023-11-27 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
MX2020004284A (es) * | 2017-10-26 | 2020-10-28 | Alexion Pharma Inc | Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua). |
EP3802593A1 (en) * | 2018-05-31 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
-
2019
- 2019-10-30 MX MX2021004994A patent/MX2021004994A/es unknown
- 2019-10-30 KR KR1020217015554A patent/KR20210084533A/ko unknown
- 2019-10-30 CA CA3118282A patent/CA3118282A1/en active Pending
- 2019-10-30 EP EP19806353.9A patent/EP3873602B1/en active Active
- 2019-10-30 ES ES19806353T patent/ES2974217T3/es active Active
- 2019-10-30 BR BR112021008063-5A patent/BR112021008063A2/pt unknown
- 2019-10-30 CN CN201980070341.7A patent/CN112996561A/zh active Pending
- 2019-10-30 AU AU2019370295A patent/AU2019370295A1/en active Pending
- 2019-10-30 EP EP23200753.4A patent/EP4306128A3/en active Pending
- 2019-10-30 EA EA202191189A patent/EA202191189A1/ru unknown
- 2019-10-30 JP JP2021519110A patent/JP2022512632A/ja active Pending
- 2019-10-30 US US17/289,178 patent/US20210395352A1/en active Pending
- 2019-10-30 WO PCT/US2019/058846 patent/WO2020092549A1/en unknown
-
2021
- 2021-04-02 IL IL281990A patent/IL281990A/en unknown
- 2021-05-13 CO CONC2021/0006290A patent/CO2021006290A2/es unknown
-
2023
- 2023-11-24 JP JP2023199206A patent/JP2024015045A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112996561A (zh) | 2021-06-18 |
AU2019370295A1 (en) | 2021-06-03 |
IL281990A (en) | 2021-05-31 |
CO2021006290A2 (es) | 2021-06-10 |
ES2974217T3 (es) | 2024-06-26 |
EA202191189A1 (ru) | 2021-08-06 |
EP3873602A1 (en) | 2021-09-08 |
KR20210084533A (ko) | 2021-07-07 |
CA3118282A1 (en) | 2020-05-07 |
JP2024015045A (ja) | 2024-02-01 |
BR112021008063A2 (pt) | 2021-08-10 |
US20210395352A1 (en) | 2021-12-23 |
EP3873602B1 (en) | 2023-12-06 |
EP4306128A2 (en) | 2024-01-17 |
EP4306128A3 (en) | 2024-03-27 |
WO2020092549A1 (en) | 2020-05-07 |
JP2022512632A (ja) | 2022-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021004994A (es) | Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh). | |
Nibu et al. | Japanese clinical practice guideline for head and neck cancer | |
MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
MY202279A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
RU2011104955A (ru) | Композиции антител | |
NZ598661A (en) | Low frequency glatiramer acetate therapy | |
NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
NZ601111A (en) | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies | |
NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
RU2012147583A (ru) | Способы лечения псориаза | |
MX2019014831A (es) | Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9. | |
EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
MX2020009265A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. | |
MX2022013923A (es) | Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23. | |
CR20220040A (es) | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab | |
JP2018522881A5 (es) | ||
RU2762499C2 (ru) | Внутрикожное введение препарата иммуноглобулина G | |
PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
MX2022001154A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
CN207804461U (zh) | 一种用于预防及处理上臂三角肌红肿、硬结的固定装置 | |
MX2021013248A (es) | Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. | |
TW202423479A (zh) | 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷(csa-aki)和/或隨後的主要不良腎事件(make)的抗c5抗體之劑量及投與 | |
Kinoshita | Linezolid/warfarin interaction | |
Miyoshi | Autologous formalin fixed tumour cell vaccine/pembrolizumab | |
Koyuncu et al. | Postmenopozal Osteoporozda Strontium Ranelat'ın Kısa Dönemde Ağrı ve Kemik mineral Yoğunluğu Üzerine Etkisi |